Cargando…

Clinicopathological Features and Prognostic Outcomes of Papillary Renal Cell Carcinoma

PURPOSE: Although papillary renal cell carcinoma (pRCC) is the second common renal malignant tumor, the current understanding of pRCC is poor. This study aims to explore the clinicopathological features and prognostic factors of pRCC. METHODS: From August 2007 and August 2017, 87 patients diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Xiaoyuan, Wan, Junlai, Qian, Can, Zhang, Jiaqiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572091/
https://www.ncbi.nlm.nih.gov/pubmed/34754225
http://dx.doi.org/10.2147/IJGM.S340569
_version_ 1784595157135392768
author Qian, Xiaoyuan
Wan, Junlai
Qian, Can
Zhang, Jiaqiao
author_facet Qian, Xiaoyuan
Wan, Junlai
Qian, Can
Zhang, Jiaqiao
author_sort Qian, Xiaoyuan
collection PubMed
description PURPOSE: Although papillary renal cell carcinoma (pRCC) is the second common renal malignant tumor, the current understanding of pRCC is poor. This study aims to explore the clinicopathological features and prognostic factors of pRCC. METHODS: From August 2007 and August 2017, 87 patients diagnosed with pRCC by postoperative pathology were enrolled. The clinicopathological features between type1 pRCC and type2 pRCC were compared by Chi-square test, Fisher’s exact test, or t-test. The Kaplan–Meier method was performed to estimate progression-free survival (PFS). Univariate and multivariate cox regression models were used to verify the prognostic factors. RESULTS: Of the 87 cases, the median tumor diameter was 5.3cm. Twenty-nine patients were diagnosed with type1 pRCC and 58 patients with type2 pRCC. According pathological stage, 59 (67.8%) cases were in pT1 stage, 19 (21.8%) in pT2 stage, and 9 (10.4%) in pT3 stage. WHO/ISUP pathological grade revealed that 56 (64.4%) patients were in grade I, 17 (19.5%) in grade II, 7 (8.05%) in grade III, and 7 (8.05%) in grade IV. The median follow-up time was 57.0months, and the 1-, 3-year PFS was 95.4%, and 80.8%, respectively. For type1 and type2 pRCC, 3-years PFS was 93.0% and 74.9%, respectively. Survival of type1 pRCC was better than that of type2 (P= 0.027). Patients with late pT stage, lymph node metastasis, distant metastasis, high pathological grade, and large size exhibited worse survival. pTNM stage, pathological grade, and tumor types were potentially related to prognosis for PFS. However, an independent prognostic factor affecting PFS was not found in multivariate regression models. For patients with the pT1 stage, nephron-sparing surgery (NSS) and radical nephrectomy (RN) did not affect the PFS, ignoring tumor types (P=0.45). CONCLUSION: Type2 pRCC is more than type1 pRCC and has an advanced TNM stage and a higher pathological grade. For patients with pRCC with the pT1 stage, the outcome of NSS is not inferior to that of RN.
format Online
Article
Text
id pubmed-8572091
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-85720912021-11-08 Clinicopathological Features and Prognostic Outcomes of Papillary Renal Cell Carcinoma Qian, Xiaoyuan Wan, Junlai Qian, Can Zhang, Jiaqiao Int J Gen Med Original Research PURPOSE: Although papillary renal cell carcinoma (pRCC) is the second common renal malignant tumor, the current understanding of pRCC is poor. This study aims to explore the clinicopathological features and prognostic factors of pRCC. METHODS: From August 2007 and August 2017, 87 patients diagnosed with pRCC by postoperative pathology were enrolled. The clinicopathological features between type1 pRCC and type2 pRCC were compared by Chi-square test, Fisher’s exact test, or t-test. The Kaplan–Meier method was performed to estimate progression-free survival (PFS). Univariate and multivariate cox regression models were used to verify the prognostic factors. RESULTS: Of the 87 cases, the median tumor diameter was 5.3cm. Twenty-nine patients were diagnosed with type1 pRCC and 58 patients with type2 pRCC. According pathological stage, 59 (67.8%) cases were in pT1 stage, 19 (21.8%) in pT2 stage, and 9 (10.4%) in pT3 stage. WHO/ISUP pathological grade revealed that 56 (64.4%) patients were in grade I, 17 (19.5%) in grade II, 7 (8.05%) in grade III, and 7 (8.05%) in grade IV. The median follow-up time was 57.0months, and the 1-, 3-year PFS was 95.4%, and 80.8%, respectively. For type1 and type2 pRCC, 3-years PFS was 93.0% and 74.9%, respectively. Survival of type1 pRCC was better than that of type2 (P= 0.027). Patients with late pT stage, lymph node metastasis, distant metastasis, high pathological grade, and large size exhibited worse survival. pTNM stage, pathological grade, and tumor types were potentially related to prognosis for PFS. However, an independent prognostic factor affecting PFS was not found in multivariate regression models. For patients with the pT1 stage, nephron-sparing surgery (NSS) and radical nephrectomy (RN) did not affect the PFS, ignoring tumor types (P=0.45). CONCLUSION: Type2 pRCC is more than type1 pRCC and has an advanced TNM stage and a higher pathological grade. For patients with pRCC with the pT1 stage, the outcome of NSS is not inferior to that of RN. Dove 2021-11-02 /pmc/articles/PMC8572091/ /pubmed/34754225 http://dx.doi.org/10.2147/IJGM.S340569 Text en © 2021 Qian et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Qian, Xiaoyuan
Wan, Junlai
Qian, Can
Zhang, Jiaqiao
Clinicopathological Features and Prognostic Outcomes of Papillary Renal Cell Carcinoma
title Clinicopathological Features and Prognostic Outcomes of Papillary Renal Cell Carcinoma
title_full Clinicopathological Features and Prognostic Outcomes of Papillary Renal Cell Carcinoma
title_fullStr Clinicopathological Features and Prognostic Outcomes of Papillary Renal Cell Carcinoma
title_full_unstemmed Clinicopathological Features and Prognostic Outcomes of Papillary Renal Cell Carcinoma
title_short Clinicopathological Features and Prognostic Outcomes of Papillary Renal Cell Carcinoma
title_sort clinicopathological features and prognostic outcomes of papillary renal cell carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572091/
https://www.ncbi.nlm.nih.gov/pubmed/34754225
http://dx.doi.org/10.2147/IJGM.S340569
work_keys_str_mv AT qianxiaoyuan clinicopathologicalfeaturesandprognosticoutcomesofpapillaryrenalcellcarcinoma
AT wanjunlai clinicopathologicalfeaturesandprognosticoutcomesofpapillaryrenalcellcarcinoma
AT qiancan clinicopathologicalfeaturesandprognosticoutcomesofpapillaryrenalcellcarcinoma
AT zhangjiaqiao clinicopathologicalfeaturesandprognosticoutcomesofpapillaryrenalcellcarcinoma